Objective-Combined oral contraceptives induce a reversible hypercoagulable state with an enhanced risk of venous thromboembolism, but the underlying mechanism(s) remain unclear. Subjects on combined oral contraceptives also demonstrate a characteristic resistance to APC (activated protein C) in the thrombin generation assay. Here, we report the potential role of plasma factor IXa (FIXa) as a mechanism for hormone-induced systemic hypercoagulability. Approach and Results-A novel assay was used to determine FIXa activity in plasma samples from volunteer blood donors.
W omen using combined oral contraceptives (COC) exhibit a 2-to 6-fold increased risk for venous thromboembolism (VTE), [1] [2] [3] [4] with the highest risk occurring during the first 6 months of use and returning to normal after discontinuation. 5 A variety of changes in procoagulant, anticoagulant, and fibrinolytic plasma protein levels have been reported in an attempt to understand the mechanisms underlying COC-associated VTE. [6] [7] [8] [9] [10] [11] Global coagulation tests have been examined similarly, with the plasma thrombin generation assay (TGA) demonstrating increased resistance to inhibition by APC (activated protein C) during COC use. 12, 13 The mechanistic basis of this observation remains unclear, but is most closely associated with decreases in full length total tissue factor pathway inhibitor α (TFPI-α) and free PS (protein S).
14 Additional clinical studies confirm that TFPI-α and free PS are consistently decreased in women using COC. 9, 15 Although originally described as an APC cofactor, PS also has APC-independent activities, including acceleration of factor Xa (FXa) inhibition by TFPI and direct inhibition of FIXa in the intrinsic tenase complex. [16] [17] [18] The former mechanism involves interaction of free PS with the Kunitz 3 and C-terminal domains of TFPI-α. 19, 20 During initiation of blood coagulation, the TF-FVIIa complex proteolytically activates FIX to FIXa and FX to FXa. 21 TFPI is the predominant regulator of TF-FVIIa activity, inhibiting the enzyme complex in a FXa-dependent manner. 22, 23 Although trace amounts of FXa generated in the initiation phase are rapidly inhibited by AT (antithrombin), isolated FIXa is poorly reactive with both its physiological substrate (FX) and inhibitor (AT). 24 Kinetic analysis of the TF-FVIIa complex in the presence of physiological TFPI and AT concentrations suggests that FIXa is the principal product of this enzyme complex. 22 Furthermore, activation of FX by the intrinsic tenase complex (FIXa-FVIIIa) represents the ratelimiting step for plasma thrombin generation (TG). [25] [26] [27] The poor reactivity of FIXa with both its substrate and inhibitor reflects the partially occluded active site of the isolated protease, which is dramatically relieved by incorporation into the FIXa-FVIIIa complex. 28 As a consequence of these structural constraints, FIXa has a markedly prolonged plasma half-life (≈41 minutes), 29 when compared with other coagulation proteases such as FXa and thrombin (<1 minute). 30, 31 Further, FIXa demonstrates enhanced potency for triggering in vivo thrombosis relative to other coagulation proteases in a rabbit jugular vein stasis assay. 32 The ability of this protease to persist in a physiological plasma milieu, participate in the rate-limiting step for TG and demonstrate marked thrombophilic potency suggests that elevated circulating FIXa levels represent a feasible mechanism for a systemic hypercoagulable state.
Modeling of the coagulation cascade suggests that physiologically relevant FIXa protease levels are <100 pmol/L. 25, 26, 33 The combination of poor protease reactivity and high in vivo potency poses a challenge for accurate FIXa activity measurements. Here, a novel method to determine plasma FIXa activity was developed using a modified TGA with FIX-deficient plasma to enhance sensitivity and a panel of inhibitory antibodies to confirm specificity. 29 This enhanced TGA (eTGA) was used to measure plasma FIXa activity in citrated plasma samples from volunteer blood donors. Total TFPI, TFPI-α, and total PS levels were measured in donor plasma, along with ex vivo analysis of TFPI and PS effects on TF-stimulated FIXa generation in FV-deficient plasma and the effect of FIXa concentration on APC resistance in the TGA. The results suggest that the increased plasma FIXa activity may represent a mechanism for systemic hypercoagulability in women using COC.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Subject Recruitment and Characteristics
Plasma samples from 116 volunteer blood donors were studied. Female blood donors were divided into 3 groups: premenopausal using hormonal contraception (PreHC, n=36), premenopausal not using hormonal contraception (PreNO, n=35), and postmenopausal (POST, n=35). Male blood donors (MEN, n=10) were included for comparison. Female blood donors ≥50-year-old not taking hormonal contraception were considered postmenopausal. Demographic data including selfdeclared ethnicity, mean age, and range are presented (Table 1) . No significant differences in mean age existed between the premenopausal female (PreHC and PreNO) or MEN groups. The 36 women in PreHC included 26 subjects on COC, 3 subjects on depot medroxyprogesterone acetate, 5 subjects on local hormonal therapy (vaginal ring or Mirena intrauterine device), and 2 using an unspecified intrauterine device. Of the 35 postmenopausal females, only 1 subject was on hormone replacement therapy (raloxifene; Table II in the online-only Data Supplement).
Plasma FIXa Activity Measurements
FIXa activity was measured using the eTGA (Figure 1 ; Figure  I in the online-only Data Supplement). In control reactions performed to characterize assay performance, plasma-derived FIXa spiked into FIX-deficient plasma exhibited stable activity (<10% variability) through 3 freeze-thaw cycles. The O1A6 antibody completely inhibited TG triggered by 50 pmol/L FXIa in FXI-deficient plasma (peak thrombin ≈200 nmol/L). Inhibitory anti-TF antibody (HTF-1) had no consistent effect on plasma FIXa activity, whereas the inhibitory anti-FIX(a) antibody (SB 249417) completely inhibited TG in all samples. Samples with activity exceeding the FIXa standard curve (30 pmol/L) were further diluted in FIX-deficient plasma before reading. Mean % coefficient of variation for FIXa determinations in premenopausal and postmenopausal women was ≈18%.
Analysis of plasma FIXa activity by blood donor group demonstrated elevated values with a skewed distribution in the PreHC subjects ( Figure 2) . A non-normal distribution of FIXa values was confirmed by the D'Agostino-Pearson omnibus test (P<0.0001) in the PreHC group, whereas values for the PreNO and POST groups were normally distributed. Based on the non-normal distribution of the PreHC group, comparisons between groups were made using the nonparametric Mann-Whitney test. Comparison of median plasma FIXa activity and interquartile range for each group confirmed that FIXa activity was significantly higher in the PreHC group compared with the PreNO, POST, and MEN groups ( Table 2 ). To isolate the effects of COC, the data were reanalyzed after restricting the PreHC group to those on COC (n=26) and exclusion of 1 subject on raloxifene in the POST group. Similar to above, FIXa activity remained significantly higher in the PreHC group compared with the PreNO, POST, and MEN groups (Table IV in the online-only Data Supplement).
Total Plasma TFPI, TFPI-α, and Total PS Antigen Measurements
Total TFPI, TFPI-α, and total PS antigen levels were determined by ELISA. Total TFPI trended modestly upwards: PreHC<PreNO<POST≅MEN groups ( Figure 3A ). Median total TFPI was significantly lower in the PreHC group compared with POST and MEN groups, but not statistically different from the PreNO group by Mann-Whitney (Table 2) . TFPI-α demonstrated a steeper upward trend from PreHC<PreNO<POST≥MEN groups ( Figure 3B ). Median plasma TFPI-α in the PreHC group was significantly lower than all other groups ( Table 2) . Total PS was lower in the premenopausal groups (PreHC and PreNO) compared with the POST and MEN values ( Figure 3C ). Similar to total TFPI, the median total PS level was significantly lower in the PreHC group compared with POST and MEN groups, but was not statistically different from the PreNO group (Table 2) . Finally, as congenital deficiency or immunodepletion of FV is associated with reduced plasma TFPI, 34 plasma FV was measured by ELISA ( Figure II in the online-only Data Supplement). No significant differences in median FV antigen were noted between groups. Reanalysis of data after restricting the PreHC group to those on COC (n=26) and exclusion of raloxifene subject in the POST group demonstrated similar differences between the PreHC group and the PreNO, POST, and MEN groups with regard to total TFPI, TFPI-α, and total PS antigen levels (Table IV in Plasma factor IXa (FIXa) activity in volunteer blood donors. FIXa activity for each subject was determined with the enhanced thrombin generation assay (eTGA). Subject plasma was preincubated with inhibitory antihuman FXIa (O1A6) antibody to block FIX activation by FXIa before dilution into FIX-deficient plasma in the presence of 8.3 µmol/L PC:PS:C, 4 nmol/L thrombin-activated FVIIIa, 40 μg/mL corn trypsin inhibitor (CTI) and the Z-Gly-Gly-Arg-AMC·HCl substrate (Methods). Fluorescence was monitored for 60 min to generate thrombin generation curves. Peak thrombin for subject plasma was compared with a standard curve to determine FIXa activity. Each data point represents the mean FIXa activity from 3 independent measurements performed on separate days. Median values±interquartile range are indicated by brackets and groups were compared using a nonparametric Mann-Whitney test (Table 2) . MEN indicates men; POST, postmenopausal women; PreHC, premenopausal women on hormonal contraception; and PreNO, premenopausal women not on hormonal contraception. According to a non-Gaussian distribution in some subgroups, median and IQR was determined for each group and a nonparametric Mann-Whitney test used to compare differences relative to the PreHC group. P value <0.05 was considered statistically significant. P values were adjusted using Bonferroni method (n=116). FIXa indicates factor IXa; IQR, interquartile range; MEN indicates healthy males; POST, postmenopausal females; PreHC, premenopausal females using hormonal contraceptives; PreNO, premenopausal females not taking hormonal contraceptives; and TFPI, tissue factor pathway inhibitor.
Correlation Between Plasma FIXa Activity, TFPI-α, and Total PS Antigen
To assess relationships between FIXa activity, TFPI, and PS antigen levels, Spearman correlation coefficients were determined for the aggregate data (n=116). As expected, total TFPI and TFPI-α demonstrated a moderate strength correlation (r s =0.57, P<0.0001), whereas total PS demonstrated a modest strength correlation with total TFPI (r s =0.33, P=0.002) and moderate strength correlation with TFPI-α antigen (r s =0.52, P<0.0001). FIXa activity did not correlate with total TFPI, but inverse correlations of modest strength were noted with both TFPI-α (r s =−0.36, P<0.0001) and total PS (r s =−0.32, Figure 4A and 4B). Finally, the relationship between TFPI-α, total PS, and FIXa activity was illustrated in a 3-dimensional plot with the 13 highest values for FIXa activity highlighted (all located in the premenopausal women on hormonal contraception group; Figure 4C ). Reanalysis of the data after restricting the PreHC group to those taking COC (n=26) as above demonstrated correlations of similar strength and statistical significance (Table III in 
P=0.002;
Effect of FIXa on TG-Based APC Resistance
Discussion
Substantial evidence links COC and hormone replacement therapy use with increased risk of VTE. [38] [39] [40] [41] Although this clinical association is well established, the mechanism(s) Figure 3 . Plasma total tissue factor pathway inhibitor (TFPI), TFPI-α, and total PS (protein S) antigen levels. A and B, Plasma total TFPI and TFPI-α were determined by bead-based proximity assay. Beads conjugated with a monoclonal antibody against the TFPI K2 domain were used with an antibody vs the TFPI K1 domain to detect total TFPI, or an antibody vs the TFPI K3 domain to detect TFPI-α. C, Plasma total PS was quantitated by commercially available ELISA. Median±interquartile range for plasma total TFPI, TFPI-α, and total PS, respectively are represented by brackets. Values for each group were compared using a nonparametric Mann-Whitney test (Table 2 ). MEN indicates men; K1, K2, and K3, respective Kunitz domains for TFPI; POST, postmenopausal women; PreHC, premenopausal women on hormonal contraception; and PreNO, premenopausal women not on hormonal contraception. underlying this induced hypercoagulability remain incompletely understood. As FIXa plays a critical role in both hemostatic and thrombotic responses in vivo, 32 the highly sensitive eTGA was developed to detect plasma FIXa activity. 29 The major findings from these studies are (1) a subset of donors on hormonal contraception demonstrate marked elevations in plasma FIXa activity, (2) elevated plasma FIXa activity correlates with reduced levels of TFPI-α and PS, (3) TFPI-α and PS directly impact the extent of TF-induced FIX activation in human plasma, and (4) increased FIXa levels induce APC resistance in the TGA. Increased APC resistance in TG-based assays has been linked to COC induced hypercoagulability. [42] [43] [44] These results suggest that elevated plasma FIXa levels represent a mechanism for hormone-induced systemic hypercoagulability.
The eTGA amplifies the FIXa signal from subject plasma via TG in FIX-deficient plasma, allowing for accurate measurement of small amounts (<10 pmol/L) of FIXa in plasma. The specificity of this assay was confirmed using inhibitory antibodies to block FXIa-dependent and TF-dependent activation of FIX within the assay and confirm the FIX(a) dependence of the TG signal. The eTGA assay has been used previously to determine contaminating FIXa levels in recombinant FIX zymogen preparations and FIXa half-life in citrated plasma. 29 The prolonged plasma half-life (≈41 minutes) of FIXa makes these measurements possible on clinical samples. Although contact activation during venipuncture is a universal issue for in vitro analysis of blood coagulation, the blood samples in this study were subject to prompt plasma isolation by a single laboratory, making it highly unlikely that variations in sample processing account for differences between blood donor groups. The most remarkable finding was the significantly increased plasma FIXa activity observed in the premenopausal women on hormonal contraception (PreHC) group (Figure 2) . FIXa activity values were significantly higher than all other groups, including the agematched premenopausal women not on hormonal contraception (PreNO; Table 2 ). The result was similar if the analysis was restricted to the 26 subjects on COC in the PreHC group (Table IV in the online-only Data Supplement). Of 116 FIXa activity determinations, the 13 highest values (≈11% total) resided in the PreHC group. In contrast, FIXa values for the premenopausal women not on hormonal contraception (PreNO) and postmenopausal women groups were not significantly different, suggesting a dominant effect of exogenous hormonal contraception over endogenous sex hormones.
Reductions in plasma TFPI and PS concentration are reported with COC exposure and linked to APC resistance in TG-based assays. 9, 10, 45 Although the majority of plasma TFPI is bound to lipoprotein particles and partially truncated, TFPI-α, also termed full-length TFPI, represents ≈10% to 30% of total TFPI. 34, 46 Although TFPI-α represents a minority of the total plasma TFPI, this full-length protein possesses the K3 domain (and C-terminus) required for interaction with PS. 20 Although total TFPI varied modestly among the groups, TFPI-α was significantly lower in the premenopausal women on hormonal contraception (PreHC) compared with the other groups, again suggesting a dominant effect of exogenous hormones (Table 2) . Similar results were found when the analysis was restricted to the 26 subjects on COC in the PreHC group (Table IV in the online-only Data Supplement). When TFPI-α was expressed as a percentage of total TFPI for each subject, mean values of 18.0%, 22.4%, and 24.7% were obtained for the PreHC, PreNO, and POST groups, respectively. When the 13 highest FIXa levels are examined, TFPI-α as a percentage of total TFPI ranges even lower (mean 13.5%). Plasmas immunodepleted of FV, FVIII, or PS have reduced levels of TFPI-α (≈20% to 40%), whereas immunodepletion of C4bBP substantially depletes total PS but does not significantly deplete TFPI. 47 TFPI-α, circulating as a complex with free PS, demonstrates substantially reduced levels in FV-deficient plasma (≈35% controls) and markedly elevated levels in patients with the East Texas Bleeding Disorder because of formation of the TFPI-α-FVshort complex. 34, 47, 48 In this study, no significant differences in FV levels were observed between groups (Figure II in the The phospholipid vesicle concentration was increased to avoid the artefactual effects of PS multimer formation. 36 All concentrations above are expressed based on total plasma volume (60 µL). *Indicates comparisons for which paired Student t test yielded P value <0.05 (similar to Figure 6 ). online-only Data Supplement), indicating that variation in FV does not account for reduced TFPI-α in blood donors on hormonal contraception. Total PS was lower in both groups of premenopausal women (PreHC and PreNO) compared with POST and MEN (Figure 3) , suggesting a dominant effect of age or endogenous sex hormones. Total PS levels were similar to previously reported values and no significant effect of hormonal contraception was noted in comparison of the agematched PreHC and PreNO groups. 49 Aggregate analysis of blood donors demonstrated a moderate strength positive correlation between TFPI-α and total PS antigen levels, consistent with the previously reported correlation for TFPI activity and total PS antigen levels. 50 Inverse correlations of modest strength were noted between FIXa activity and both total PS and TFPI-α (but not total TFPI; Figure 4 ). These correlations were similar when the analysis was restricted to the 26 subjects on COC in the PreHC group (Table III in the online-only Data Supplement). The lack of free PS levels is a limitation of the current study, as (1) free PS is the relevant form that binds TFPI-α to accelerate FXa inhibition and (2) C4bBP binding to PS likely antagonizes the ability to bind TFPI-α. 51 Free PS levels would be expected to correlate more tightly with TFPI-α and inversely with FIXa activity.
Previous studies using purified proteins have found (1) FIXa is the major product of TF-FVIIa with TFPI and AT present and (2) free PS enhances TFPI-α potency for inhibition of FIX activation. 16, 22, 23 Here, we examined TF-triggered FIXa generation in FV-deficient plasma. Inhibitory antibodies directed against the TFPI K1 and K2 domains markedly enhanced FIXa generation ( Figure 5A ), consistent with the importance of TFPI in FXa-dependent inhibition of TF-FVIIa. TFPI-α supplementation had no effect in low phospholipid ( Figure 5A ), but significantly reduced FIXa generation in high phospholipid ( Figure 5B), consistent with the reduced K I for TFPI-α inhibition of TF-FVIIa under the former conditions. 23 Free PS supplementation reduced FIXa generation in the presence or absence of exogenous TFPI-α, consistent with the role of PS in accelerating the rate-limiting step (TFPI-FXa complex formation) for inhibition of TF-FVIIa. 16 The effects of TFPI-α and free PS on plasma FIXa generation are consistent with the inverse correlation observed between these inhibitors and plasma FIXa activity (Figure 4) . Additionally, increasing FIXa concentration demonstrated a progressive increase in APC resistance in TF-triggered TGA (Figure 6 ). Given the rate-limiting nature of FIXa for TG, the observed APC resistance likely represents rebalancing of the thrombin response rather than an APC specific mechanism. Thus, hormone-induced reductions in TFPI-α and free PS may lead to both elevated plasma FIXa activity and the APC resistance phenotype.
FIXa controls the rate-limiting step for TG, 27,33 possesses potent in vivo thrombogenicity 32, 52 and persists as an active protease in plasma, 29 suggesting that elevated circulating protease levels represent a mechanism for systemic hypercoagulability. The heterogeneous elevation in FIXa activity observed here may identify women on hormonal contraception at highest risk of VTE. The current study is limited by the cross-sectional nature of the analysis, heterogeneity of hormonal contraceptive therapies, and lack of clinical end points. Although hormone-induced reduction in TFPI-α and free PS is a feasible mechanism for increased FIXa activity, the relative strength of inverse correlations between subject inhibitor levels and FIXa activity suggests that additional factors may be involved. Family history of hormone-associated VTE is associated with increased VTE risk in female relatives, suggesting that genetic variation in subject response may impact estrogen metabolism, signaling, or gene regulation. 53, 54 Estrogens regulate a broad array of genes, including FXII, which may enhance FIXa generation via the intrinsic pathway. [55] [56] [57] Future studies will target the longitudinal effects of COC exposure on plasma FIXa activity and alternative mechanisms for FIXa generation.
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